Medical Products M&A Landscape In 2026

UK Medical Products M&A In 2026

The UK medical products market continues to attract significant M&A activity, driven largely by private equity-backed platforms pursuing buy-and-build strategies across a fragmented sector.

The most interesting point, however, is not simply that deals are happening. It is that the most attractive assets appear to be relatively scarce, particularly where businesses combine strong NHS relationships, differentiated products, UK manufacturing capability or recurring service revenues.

Recent transactions across Vernacare, Mediq, Asker Healthcare Group, Prism Healthcare, GBUK Group and DHCare show a clear pattern. Consolidators are not simply buying revenue or pursuing broad geographic roll-ups. They are acquiring adjacent capabilities that make them more relevant to existing clinical workflows, procurement routes and care delivery settings.

Vernacare, backed by H.I.G. Capital, has expanded from its infection prevention core into surgical consumables and women’s health through acquisitions including Robinson Healthcare, Splice Cast and Eakin Surgical. GBUK Group, backed by A&M Capital Europe, has moved beyond enteral feeding and vascular access into patient handling, ENT, neuro-otology, endoscopy and specialist surgical devices through deals including Care & Independence, Severn Healthcare and GS Medical.

Prism Healthcare has followed a slightly different but equally consistent strategy, building a broader patient handling and long-term care equipment platform across successive private equity ownership cycles. Its acquisition of Joerns Healthcare UK and the Oxford product range strengthened its position in hoists, slings, bathing and acute care products.

Mediq and Asker Healthcare Group demonstrate the pan-European angle. Mediq entered the UK through H&R Healthcare before scaling through Bunzl Healthcare and C&P Medical. Asker used Hospital Services Limited as its UK and Ireland platform, then added complementary healthcare software and surgical technology capabilities through Health Net Connections and Novus Med.

Across these examples, the strategic logic is remarkably consistent. The strongest platforms are combining products, service, installation, training, maintenance, rental and logistics to become more embedded partners to healthcare providers. NHS access remains a critical moat, but it is most valuable when combined with clinical credibility, service infrastructure and proprietary or specialist product capability.

UK manufacturing also appears to be an increasingly relevant part of the story in certain categories. In a market shaped by supply chain pressure, procurement scrutiny and regulatory complexity, domestic manufacturing is no longer just a nice feature. For some product areas, it can form part of the investment case.

The market now appears to be entering a more mature phase. Earlier deals were focused on creating platforms. More recent activity is about sharpening category leadership, broadening care pathway exposure and building larger, more strategic assets. The combination of Direct Healthcare Group and Invacare’s international operations into DHCare is a good example of where the sector may be heading.

Overall, the UK medical products market remains highly attractive for investors, but buyer appetite is becoming more selective. The assets likely to command the strongest interest are those with credible NHS access, differentiated products, recurring service-led revenue and the operational infrastructure to support further consolidation.